MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors
05 avr. 2022 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., April 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine...
Interpace Diagnostics Group Reports Full Year and Fourth Quarter 2018 Financial Results
19 mars 2019 16h05 HE
|
Interpace Diagnostics Group, Inc.
Business Progress and Recent Accomplishments Highlighted and Discussed Further on Conference Call PARSIPPANY, NJ, March 19, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:...
Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris
17 janv. 2018 07h00 HE
|
Strongbridge Biopharma plc
~ MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder ~ ~ MACRILEN is Strongbridge’s Second Commercial...
Strongbridge Biopharma plc Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
27 juin 2017 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., June 27, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016
06 sept. 2016 09h00 HE
|
XOMA Ltd.
BERKELEY, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it will host a webcast and...
XOMA Reports Second Quarter 2016 Achievements and Financial Results
03 août 2016 16h01 HE
|
XOMA Corporation
BERKELEY, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and...
XOMA Initiates Phase 2 Proof-of-Concept Study of XOMA 213
28 juin 2016 09h01 HE
|
XOMA Corporation
BERKELEY, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its Phase...
Strongbridge Biopharma plc to Participate in the JMP Securities Life Sciences Conference and 3rd Annual ROTH Healthcare Day in London
14 juin 2016 07h30 HE
|
Strongbridge Biopharma plc
DUBLIN, Ireland and TREVOSE, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease biopharmaceutical company focused on the development and...
XOMA Reports First Quarter 2016 Operational Achievements and Financial Results
04 mai 2016 16h01 HE
|
XOMA Corporation
BERKELEY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent operational...
XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
04 avr. 2016 09h00 HE
|
XOMA Corporation
BERKELEY, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from...